Unexpected drug combo boosts weight loss in women 50+ by 35%

A recent study led by Mayo Clinic has discovered that a common menopause treatment might boost weight loss when combined with a popular weight-loss medication. These findings could open new avenues for better managing weight and health risks for women after menopause.

Menopause, a natural phase in life, typically occurs in women’s late 40s or early 50s. During this time, estrogen production declines, causing symptoms like hot flashes, disrupted sleep, and mood swings.

This hormonal change can also make it easier to gain weight, especially around the belly. Excess weight in this area raises the risk of serious conditions such as heart disease and type 2 diabetes.

Many women opt for menopausal hormone therapy to relieve symptoms, which helps replace some of the lost estrogen. While this treatment can improve quality of life, scientists haven’t fully understood whether it also influences weight management.

Meanwhile, new weight-loss medications have entered the market. One of these is tirzepatide, FDA-approved for people with overweight or obesity. It functions by suppressing appetite and regulating blood sugar, promoting weight reduction.

Researchers set out to explore whether hormone therapy could enhance the effects of tirzepatide. They analyzed data from 120 adults who used the medication for at least a year.

Some of these women were also on hormone therapy, while others were not. To ensure a fair comparison, the researchers matched the groups based on their starting conditions.

The results revealed a notable difference: women combining hormone therapy with tirzepatide experienced approximately 35% more weight loss than those using just the medication. This substantial difference suggests potential synergy between the treatments.

The findings appeared in The Lancet Obstetrics, Gynecology, & Women’s Health. Lead author Dr. Regina Castaneda noted that these insights might help healthcare providers develop more tailored treatment strategies for postmenopausal women.

However, the study’s authors also acknowledged that this observational research doesn’t definitively prove that hormone therapy directly causes the increased weight loss. Other factors could be influencing the results.

For instance, women opting for hormone therapy may also be more diligent about maintaining healthy habits, such as balanced eating and regular exercise. Additionally, symptom relief might improve sleep quality and boost motivation for lifestyle changes.

There’s also interest in understanding how estrogen might interact with weight-loss drugs. Early evidence suggests that estrogen could enhance the appetite-suppressing effects of medications like tirzepatide, possibly explaining the greater weight loss observed with combined treatment.

Researchers are now planning further investigations, including clinical trials, to confirm these preliminary findings. They also aim to examine whether this combination can positively impact other health indicators, such as blood sugar, cholesterol, and heart health.

Overall, this study highlights a promising new approach to supporting women through menopause. Combining treatments could yield better results than relying on a single method.

From an analytical standpoint, the early evidence indicates a significant and clinically relevant link between hormone therapy and weight-loss medication. Yet, due to the study’s design and small sample size, more rigorous trials are needed before healthcare providers can make firm recommendations. Nevertheless, these findings pave the way for future research and potential new therapies.

If weight management interests you, consider exploring articles about diets that can treat fatty liver disease and obesity and hop extract and its potential to reduce belly fat in overweight individuals.

For additional insights into weight control, see recent studies on how to curb cravings for processed foods and foods that can boost your metabolism.

Source: Mayo Clinic.